Avtor/Urednik		Gregorič-Kumperščak, Hojka
Naslov		Uporaba selektivnih inhibitorjev ponovnega privzema serotonina v razvojnem obdobju
Prevedeni naslov		Serotonin selective reuptake inhibitors use in children and adolescents
Tip		članek
Vir		Zdrav Vestn
Vol. in št.		Letnik 69, št. 10
Leto izdaje		2000
Obseg		str. 683-7
Jezik		slo
Abstrakt		Background. Serotonine selective reuptake inhibitors (SSRI) are relatively new antidepressants. In terms of use they are not just limited to the treatment of depression in adults, but have broader indications such as obsessive-compulsive disorders (OCD) and eating disorders. In addition they are administered in the treatment of children and adolescents disorders, even though studies and clinical experience is more sparse than in adults. With one exception, SSRI are not registered for the treatment of children and adolescents, even though they are second most commonly prescribed psychotropic medications in this age group. This article summarizes published clinical experience with SSRI in the treatment of children and adolescents. A short comparison of pharmacodynamics, pharmacokinetics and SSRIs side effects in adults, children and adolescents is given. Also discussed is labeling issue concerning the prescribing SSRIs in this age group. Conclusions. The reports described clinical effects of treatment with SSRIs, mostly benefits, for 13 indications. The most convincing evidence for efficacy for SSRIs in adolescents exists for treatment of depression and OCD. Only sparse evidence, mostly anecdotical, exists for SSRI efficacy in other conditions. Sertraline was recently registered for treatment of OCD in 6-17-year-olds in Slovenia.
Izvleček		Izhodišča. Selektivni inhibitorji ponovnega privzema serotonina (SSRI) so sorazmerno novi antidepresivi. Uporabljajo se ne le za zdravljenje depresije pri odraslih, ampak imajo širše indikacije, npr. obsesivno-kompulzivne motnje (OKM), motnje hranjenja. Uporaba SSRI pri otrocih in mladostnikih ni podprta s tolikimi študijami in kliničnimi izkušnjami kot pri odraslih. Razen ene izjeme SSRI niso registrirani za zdravljenje v razvojnem obdobju, čeprav so druga najbolj predpisovana psihotropna zdravila v tej starostni skupini. Prispevek povzema objavljene klinične izkušnje uporabe SSRI v razvojnem obdobju. Na kratko je podana primerjava farmakodinamike, farmakokinetike in stranskih učinkov SSRI pri odraslih, otrocih in mladostnikih. Obravnavano je tudi vprašanje (ne) upravičenosti predpisovanja neregistriranih zdravil v razvojnem obdobju. Zaključki. Pregled literature pokaže, da so bili SSRI uspešno uporabljeni pri vsaj 13 indikacijah v razvojnem obdobju. Največ prepričljivih študij uspešnosti SSRI v tem starostnem obdobju je za zdravljenje depresije in obsesivno-kompulzivne motnje (OKM). Le posamezne, majhne študije in anekdotični primeri kažejo na uspešnost zdravljenja s SSRI pri drugih motnjah. Sertralin je pred kratkim registriran za OKM v starosti od 6. do 17. leta tudi v Sloveniji.
Deskriptorji		DEPRESSIVE DISORDER SEROTONIN UPTAKE INHIBITORS CHILD ADOLESCENCE OBSESSIVE-COMPULSIVE DISORDER NUTRITION DISORDERS ANOREXIA NERVOSA BULIMIA AUTISM ANXIETY DISORDERS ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY